作者: David G. Hicks , Raymond R. Tubbs
DOI: 10.1016/J.HUMPATH.2004.11.010
关键词:
摘要: Diagnostic assays for HER2 in breast cancer provide important prognostic information and independently help guide management by identifying patients who are the most likely to benefit from Herceptin-targeted therapy. The biological events underlying -driven that can be assessed routine clinical specimens include evaluation of gene amplification fluorescence situ hybridization (FISH), enhanced messenger RNA expression real-time polymerase chain reaction, assessment protein overexpression at tumor cell membrane immunohistochemistry (IHC). Immunohistochemistry FISH methodologies have advantage being morphologically driven, allowing correlations between morphologic features. However, each has advantages disadvantages, which discussed detail. Although is familiar readily accommodated surgical pathology laboratories, increasing demands testing setting will require greater familiarity with technical aspects their interpretation laboratory community. In this review, we an overview cancer, emphasis on considerations, interpretive guidelines, scoring criteria, quality control. development automated platforms hybridization, image analysis signal enumeration, experience should broaden availability technology diagnostic testing.